glp-1 gastric emptying anesthesia A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general glp 1 gastric emptying anesthesia
Description
Findings from the ATTAIN Phase III clinical trial programme investigating orforglipron as a tool for weight management will be shared later in 2025
In the cohort not using CPAP at baseline, the mean AHI dropped by approximately 27 events per hour
Below we compare the major differences, pros and cons, and real-world considerations so you can make an informed choice with your provider
This phenomenon is not unique to GLP-1splateaus happen in any regimen, including diets, exercise, and bariatric surgery
